Login
$ACRV
$1.45 -$0.01 (0.68%) Pre-market

$ACRV SEC Filings

Filed On Filing
16 Nov 2026 S-3
16 Nov 2026 8-K: Results of Operations and Financial Condition

Immunology and inflammation (I&I) established as a second strategic pillar for company which is particularly well-suited for its AP3 precision medicine approach

16 Nov 2026 10-Q
10 Nov 2026 8-K: Regulation FD Disclosure

CORPORATE R&D AND KOL EVENT ACRIVON’S NEW I&I PROGRAMS DIFFERENTIATED ASSETS IDENTIFIED WITH PROPRIETARY AP3 PLATFORM NOVEMBER 10, 2026 Exhibit 99.1

06 Nov 2026 8-K: Other Events

Acrivon Expands into Immunology and Inflammation with Acquisition of Phase 2-Ready Differentiated, Oral JAK1 Inhibitor ACR-525, and PKCθ Inhibitor Preclinical Program from Aqilion AB

26 Oct 2026 Form 4: Miller Mary, Chief Legal Officer

Sold 513 shares ($944)

07 Oct 2026 Form 4: Miller Mary, Chief Legal Officer

Sold 294 shares ($585)

02 Sep 2026 Form 4: Levin Michaela, Chief Business Officer

Received 30,000 shares as a grant or award · Granted 130,000 Stock Option (Right to Buy)

02 Sep 2026 Form 3: Levin Michaela, Chief Business Officer

No securities owned

27 Aug 2026 Form 4: Blume-Jensen Peter, Director and 1 other

Sold 14,036 shares ($31K)

25 Aug 2026 144
20 Aug 2026 Form 4: Peterson Katharine, Chief Accounting Officer

Sold 101 shares ($203)

20 Aug 2026 Form 4: Miller Mary, Chief Legal Officer

Sold 185 shares ($372)

20 Aug 2026 Form 4: Gamelin Erick, Chief Development Officer

Sold 400 shares ($804)

20 Aug 2026 Form 4: Devroe Eric, Chief Operating Officer

Sold 604 shares ($1.21K)

20 Aug 2026 Form 4: Blume-Jensen Peter, Director and 1 other

Sold 1,713 shares ($3.44K)

13 Aug 2026 SCHEDULE 13G/A
12 Aug 2026 S-8
12 Aug 2026 8-K: Results of Operations and Financial Condition

ACR-368 Phase 2b prespecified interim analysis and data from all-comer serous endometrial cancer (EC) treatment arms on track for second half of 2026

12 Aug 2026 10-Q

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support